Zhang Rui, Yan Pang-Ke, Zhou Cai-Hong, Liao Jia-Yu, Wang Ming-Wei
The National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Acta Pharmacol Sin. 2007 Jan;28(1):125-31. doi: 10.1111/j.1745-7254.2007.00451.x.
To develop homogeneous calcium mobilization assay for high-throughput screening (HTS) of mas-related gene (Mrg) receptor agonists.
CHO-K1 cells stably expressing the full-length MrgD receptor and a calcium-sensitive dye were used to develop an HTS assay based on intracellular calcium influx. This method was applied to large-scale screening of a library containing 8000 synthetic compounds and natural product extracts. cAMP measurements were carried out to verify the bioactivities of the hits found by the calcium mobilization assay. Similar approaches were also employed in the identification of the MrgA1 receptor agonists following HTS of 16,000 samples.
EC(50) values of the positive control compounds (beta-alanine for MrgD receptor and dynorphin A for MrgA1 receptor) determined by the calcium mobilization assay were consistent with those reported in the literature, and the Z' factors were 0.65 and 0.50 for MrgD and MrgA1 receptor assay, respectively. About 31 compounds for the MrgD receptor and 48 compounds for the MrgA1 receptor showing > or =20% of the maximal agonist activities found in the controls were initially identified as hits. Secondary screening confirmed that 2 compounds for each receptor possessed specific agonist activities. Intracellular cAMP level measurements indicated that the 2 confirmed hits displayed the functionality of the MrgD receptor agonists.
A series of validation studies demonstrated that the homogeneous calcium mobilization assay developed was highly efficient, amenable to automation and a robust tool to screen potential MrgD and MrgA1 receptor agonists. Its application may be expanded to other G-protein coupled receptors that mobilize calcium influx upon activation.
开发用于Mas相关基因(Mrg)受体激动剂高通量筛选(HTS)的均相钙动员测定法。
使用稳定表达全长MrgD受体和钙敏染料的CHO-K1细胞,开发基于细胞内钙内流的HTS测定法。该方法应用于大规模筛选包含8000种合成化合物和天然产物提取物的文库。进行cAMP测量以验证通过钙动员测定法发现的命中物的生物活性。在对16000个样品进行HTS后,在鉴定MrgA1受体激动剂时也采用了类似方法。
通过钙动员测定法测定的阳性对照化合物(MrgD受体的β-丙氨酸和MrgA1受体的强啡肽A)的EC(50)值与文献报道一致,MrgD和MrgA1受体测定的Z'因子分别为0.65和0.50。最初鉴定出约31种MrgD受体化合物和48种MrgA1受体化合物,其显示出对照中发现的最大激动剂活性的≥20%,为命中物。二次筛选证实每种受体有2种化合物具有特异性激动剂活性。细胞内cAMP水平测量表明,2种经确认的命中物表现出MrgD受体激动剂的功能。
一系列验证研究表明,所开发的均相钙动员测定法高效、易于自动化,是筛选潜在MrgD和MrgA1受体激动剂的可靠工具。其应用可能扩展到其他激活后动员钙内流的G蛋白偶联受体。